Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
Researchers developed a new approach to overcome treatment resistance in aggressive cancers by activating macrophages, a type of immune cell abundant in advanced tumors. The custom anti-αvβ3 antibody triggers powerful anti-tumor responses and is highly selective, making it a potentially safer alternative.
A newly identified antibody, 04_A06, has been found to block 98.5% of over 300 different HIV strains in laboratory tests. In humanized mice models, the antibody reduced viral load to undetectable levels, offering a promising approach for HIV prevention and treatment.
A team of international researchers, led by UC Riverside's Scott Pegan, are developing protective antibodies against CCHFV using monoclonal antibody treatments and exploring non-traditional viral targets. The study aims to identify life-saving therapeutics for future nairovirus outbreaks.
A study comparing immunoblot assays and ELISA for detecting anti-F-actin antibodies in autoimmune hepatitis type 1 reveals comparable accuracy, with immunoblotting providing higher specificity. The findings suggest that immunoblot assays could be a reliable alternative to ELISA for diagnostic purposes, but larger studies are needed.
A Japanese study has identified four distinct patterns of immune response after COVID-19 vaccines, with a 'rapid-decliner' group experiencing faster decline in antibody levels. Monitoring changes in antibody levels may help identify individuals at greater risk of infection and inform more effective vaccination strategies.
Researchers have found a way to use antibodies to direct T cells to kill Cytomegalovirus-infected cells, offering an alternative treatment for life-threatening infections without expensive and side-effect-prone drugs.
Researchers at UMass Amherst found that certain T-cells have an inherent ability to remember past viral foes, which could lead to next-generation cancer vaccines. This 'immunological memory' is crucial for the body's immune response and can be harnessed for targeted therapies.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Researchers found that a high fiber diet reduced Alzheimer's-related frailty and tremor in mice by restoring balance in the gut immune system. This discovery provides a potential new therapeutic pathway for the disease.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
A team of researchers at Mount Sinai discovered three powerful monoclonal antibodies that target the viral protein A35 and block viral spread in laboratory tests. These antibodies also protected rodents from severe disease and fully prevented death, suggesting they could be promising drug candidates for mpox treatment.
Researchers developed a new method to identify functional plasma antibodies against malaria using mass spectrometry sequencing, providing valuable insight into protective antibody responses. The study identified a broadly neutralizing antibody with broad inhibitory activity against diverse PfEMP1 variants.
The R21/Matrix-M malaria vaccine generates nearly identical antibodies to those following a natural infection, providing strong protection against the earliest life stage of malaria parasites. This long-lasting immunity is effective without requiring further adaptation.
Researchers discovered how glycosylation modulates IgG antibody architecture, enabling precision immunotherapies for cancer and autoimmune diseases. The study's findings highlight the power of integrating experimental and computational approaches to decode glycoprotein dynamics and optimize clinical performance.
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
A study published in Nature found that autoantibodies can tilt the odds dramatically toward shrinking tumors and enhance the effectiveness of immunotherapy. Certain autoantibodies linked to better clinical outcomes could reveal cancer's weak spots and point to new targets for treatment.
Scientists have designed a nanobody made from llama antibodies to activate a glutamate receptor involved in neural activity, improving cognitive function in mouse models of schizophrenia. Peripheral administration has shown promise as a new therapeutic strategy for treating the condition.
Researchers discovered a new monoclonal antibody, 2B010, that selectively targets regulatory T cells (Tregs) in tumors, boosting the activity of CD8+ T cells and improving anti-tumor immune responses. This unique mechanism could complement existing cancer therapies and lead to more effective treatments.
Researchers at Scripps Research Institute have developed a new microchip that can reveal how antibodies interact with viruses, allowing for faster and clearer insights into vaccine development. The technology offers a quicker-than-ever method to analyze antibody interactions, enabling scientists to design more effective vaccines.
Researchers are creating a single-cell atlas to identify potent antibody therapies against measles, mumps, and rubella viruses. The goal is to accelerate antibody discovery and inform vaccine design.
Researchers at University of Queensland have discovered a nanobody to combat two highly lethal viruses with no approved vaccine or cure. The DS90 nanobody can access hard-to-reach areas of the virus to block infection.
Deepshika Ramanan, a Salk Assistant Professor, has been recognized as a Rita Allen Foundation Scholar for her innovative research on maternal immunity and lactation. She will receive annual grants of up to $110,000 to conduct groundbreaking work in neuroscience, cancer, immunology, and pain.
Researchers at Mass General Hospital discovered that humans are born with a genetic predisposition to develop IgG antibodies to peanut proteins. These findings have significant implications for the treatment and prevention of food allergies.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers identified specific antibody features that limit Mtb growth, revealing critical insights into antibody-immune cell interactions. The study lays groundwork for potential antibody-based therapies or vaccines against tuberculosis, an urgently needed treatment for the deadly infectious disease.
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
The new Epigraph vaccine developed by University of Nebraska-Lincoln virologist Eric Weaver protects against H1N1 swine flu and can also protect against influenza in humans and birds. The vaccine significantly outperformed commercial vaccines, providing protection for up to a decade.
Scientists have engineered a monoclonal antibody that protects mice from a lethal dose of influenza A with sticky staying power. The new molecule combines specificity and broad binding capacity, adhering to the lung lining and blocking infection in mice.
Researchers at Scripps Research used computer modeling to illustrate how antibodies recognize lipids in the HIV virus, highlighting a potential new approach for vaccine design. The study identified two key structural features on the antibodies that enable them to target well-defined membrane features.
A clinical trial is underway to assess the effectiveness of sipavibart, a long-acting monoclonal antibody, in treating Long COVID symptoms. The study aims to improve patients' health and restore them to full health.
A topical BRAF-inhibiting gel, LUT014, improved acneiform rash in 69% of patients with grade 2 or 3 rash and received an EGFR-targeted antibody. The treatment also showed a 33% success rate for the placebo arm, but was associated with similar adverse events.
The CoVaRR-Net network successfully bridged critical research and public health gaps exposed by the COVID-19 pandemic through interdisciplinary collaboration and innovative approaches like wastewater surveillance. Its achievements include 139 peer-reviewed publications, evidence-based public health decisions, and a global leader in ear...
A new study from Scripps Research finds that a higher ratio of antibodies to viral protein better engages two specific types of immune cells, including phagocytes and natural killer cells. This discovery has implications for the development of experimental HIV vaccines and other drugs.
Researchers developed fluorescent polyionic nanoclays that can be customized for medical imaging, sensor technology, and environmental protection. These tiny clay-based materials exhibit high brightness and versatility, enabling precise tuning of optical properties.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
A new point-of-care technology developed by Northwestern University scientists can detect multiple HIV antigens at high sensitivity in a matter of minutes. The technology uses a nanomechanical platform and tiny cantilevers to measure the binding of p24 antigens to surface antibodies, demonstrating high specificity.
A new study by researchers at McGill University found that annual COVID-19 vaccine booster doses help avoid breakthrough infections in people with immune-mediated inflammatory diseases. The study tracked 366 patients across Canada and used saliva PCR tests and antibody measurements, offering a more precise picture of infection risks.
A study estimated the epidemiology of hepatitis D virus (HDV) in China, finding a prevalence of HDV antibody positivity among 4,936 patients with chronic HBV infection. The rate was 0.24%, with only one patient having both anti-HDV antibody and HDV RNA positivity.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
A new study by UNC Charlotte researchers reveals the H5N1 influenza virus is adapting to escape human immunity, increasing the risk of transmission in humans. The team's computational modeling finds a worsening trend in antibody affinity to more recent viral isolates, indicating a greater risk to human health.
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
A recent study published in the Journal of Experimental Medicine reveals that plasma cells are programmed from birth to migrate to protected sites in the body, where they produce large amounts of antibodies. High expression of integrin β7 is an excellent marker for these cells' ability to home to the bone marrow.
Research finds that certain viral antibodies and genetic risk factors can increase MS risk, with elevated antibody levels combined with a specific gene variant associated with strong increased risk. The study also identifies potential biomarkers for early diagnosis.
A new study has discovered how antibodies help protect against Strep A infections and is contributing to the development of a Strep A vaccine. The research used the world's only human challenge model for Strep A, which uncovered the power and potential for this model to accelerate vaccine development.
Researchers at Stanford University have discovered a method to use two antibodies to effectively combat the constantly evolving virus, which could lead to longer-lasting treatments for COVID-19. The antibodies were shown to be effective against all SARS-CoV-2 variants in laboratory testing.
A longitudinal study found that EBV infection predisposes people to develop Crohn's disease, with a five-to-seven-year delay between exposure and diagnosis. The study suggests that EBV may alter the immune system leading to Crohn's disease.
Researchers developed a simple test that detects antibodies against four dengue virus serotypes and zika virus. The test achieved high sensitivity (87.8%) and specificity (91.4%), indicating its potential to monitor specific antibodies produced in response to exposure to the viruses.
A blood test has been found to identify personalized dietary triggers for patients with irritable bowel syndrome, resulting in improved abdominal pain relief. The study showed that 59.6% of participants who removed trigger foods experienced significant reduction in abdominal pain compared to 42.2% in the control group.
Researchers discover how an anticancer drug triggers an 'outside in' signal to get sucked into a cancer cell, providing insights into adhesion regulation and potential drug design targets. The study reveals a new mechanism for delivering drugs using P-cadherin protein.
Researchers developed MUNIS, a deep learning tool that predicts CD8+ T cell epitopes with high accuracy, potentially accelerating vaccine development. The tool was validated using experimental data from influenza, HIV, and EBV, demonstrating its potential to streamline vaccine design.
Researchers at Duke University developed an acoustofluidic integrated molecular diagnostics chip, AIMDx, that uses tiny vortexes to detect dangerous viruses. The vortexes trap cells, bacteria, and larger bioparticles, purifying samples for biomedical tests.
Scientists discovered that repetitive HIV vaccinations can lead to the production of antibodies targeting immune complexes already bound to the virus. This chain reaction was observed in follow-up experiments on HIV-vaccinated animals and may impact vaccine design strategies. Understanding this response could lead to improved vaccines ...
Researchers from McGill University and colleagues found that stunted children had lower levels of antibodies against measles by age five. The study suggests that combatting child hunger could help prevent measles outbreaks globally, as undernutrition may affect vaccine protection.
A consensus platform for antibody characterization has been developed to evaluate antibody specificity and tackle the challenge of non-specific antibodies in life sciences. The Open Science approach supports large-scale collaboration among competitors in the antibody industry, resulting in an estimated $1 billion annual savings.
A new hepatitis B vaccine, Heplisav-B, has been shown to be more effective than an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination. The study found that up to 99.4% of subjects received the new vaccine showed protective levels of antibodies.
Researchers chart high-precision map of aging across various organs and reveal immunoglobulin's dual-edged sword effect on systemic aging. The study identifies key hallmarks of aging, including tissue structural disorder and loss of cellular identity.
The study analyzed antibody profiles from humans in three countries to reconstruct historical seasonal influenza patterns and individual lifetime infection histories. The findings revealed variation in incidence and antibody dynamics over the life course.
Research led by ISGlobal reveals that children younger than five months of age may benefit from the RTS,S and R21 malaria vaccines if they live in areas with low malaria transmission, where mothers have less antibodies to the parasite. The study analyzed blood samples from over 600 children and infants and found that high levels of mat...